









Markets
/
Stocks
/
nasdaq-vcel
/

Vericel Corp

VCEL

34.530USD

-0.350-1.00%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

1.74BMarket Cap

245.07P/E TTM



Vericel Corp

34.530

-0.350-1.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vericel Corp

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vericel Corp's Score

Industry at a Glance

Industry Ranking

50 / 159

Overall Ranking

144 / 4621

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

53.500

Target Price

+53.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vericel Corp Highlights

StrengthsRisks

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 44.33% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 225.27, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 56.93M shares, decreasing 1.25% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 13.66K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 7.44, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 63.24M, representing a year-over-year increase of 20.09%, while its net profit experienced a year-over-year increase of 88.19%.

Score

Industry at a Glance

Previous score

7.44

Change



Financials

7.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.74

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.64

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.56

Key Metrics

Free cash flow

No Data

Vericel Corp's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 5.14, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 225.27, which is 2017.45% below the recent high of 4770.06 and 447.43% above the recent low of -782.68.

Score

Industry at a Glance

Previous score

5.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 50/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 8.50, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Vericel Corp is 55.00, with a high of 62.00 and a low of 41.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

53.500

Target Price

+53.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Vericel Corp

VCEL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 7.25, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 37.23 and the support level at 31.58, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.78

Change

-1.53

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.045

Buy

RSI(14)

49.987

Neutral

STOCH(KDJ)(9,3,3)

36.371

Sell

ATR(14)

1.566

Low Volatility

CCI(14)

-39.859

Neutral

Williams %R

45.896

Neutral

TRIX(12,20)

0.495

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

35.806

Sell

MA10

35.924

Sell

MA20

34.688

Sell

MA50

33.650

Buy

MA100

36.491

Sell

MA200

41.982

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.81. The latest institutional shareholding proportion is 112.82%, representing a quarter-over-quarter decrease of 0.58%. The largest institutional shareholder is The Vanguard, holding a total of 3.55M shares, representing 7.04% of shares outstanding, with 0.02% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.01M

-3.50%

The Vanguard Group, Inc.

Star Investors

3.55M

+2.01%

Brown Capital Management, LLC

2.81M

-2.43%

State Street Investment Management (US)

2.44M

-0.07%

Conestoga Capital Advisors, LLC

2.46M

+19.50%

Fidelity Management & Research Company LLC

1.97M

-9.88%

Geneva Capital Management LLC

1.78M

+30.69%

Invesco Advisers, Inc.

1.77M

-10.80%

Congress Asset Management Company, LLP

1.74M

+17.99%

GW&K Investment Management, LLC

1.41M

-1.25%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 5.00, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.41. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.